Patent intelligence · US
US 10668062
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
Patent details — US 10668062
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 2, 2020
- Expiration
- May 28, 2040
- Applicant
- Lixte Biotechnology, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K31/4178, A61K31/4525
Quick answer
US 10668062 (Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Jun 2, 2020. Expires May 28, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lixte Biotechnology, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K31/4178, A61K31/4525, A61K31/496, A61P
More from Lixte Biotechnology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343342
Methods for treating soft tissue sarcoma
granted -
US 11931354
Formulations of oxabicycloheptanes and oxabicycloheptenes
granted -
US 11866444
Oxabicycloheptane prodrugs
granted -
US 11236102
Oxabicycloheptane prodrugs
granted -
US 10618908
Oxabicycloheptane prodrugs
granted -
US 10532050
Formulations of oxabicycloheptanes and oxabicycloheptenes
granted -
US 10434100
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
granted
Frequently asked questions
What is US patent 10668062?
US 10668062 (Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Jun 2, 2020. Expires May 28, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10668062?
Lixte Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 10668062 expire?
Our index shows an expiration date of May 28, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.